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After Repeated Administration: An Interoceptive Drug State Mechanism
Alexa Lucille Mead, Department of Psychology, University of Nebraska-Lincoln, USA
Ming Li, Department of Psychology, University of Nebraska-Lincoln, USA (mli2@unl.edu)

Abstract

during the acquisition phase of avoidance conditioning
exhibited significantly fewer avoidance responses when
they were retested 3 weeks later to the same drug in comparison to rats that were previously treated with nonantipsychotic drugs (chlordiazepoxide, 10 mg/kg, citalopram 10 mg/kg, or sterile water). Overall, these findings
indicate a ‘drug memory’-like mechanism that maintains
the avoidance-suppressing effect of antipsychotics over
time. This mechanism is likely driven by the interoceptive state caused by the antipsychotics, which may also
be an important behavioral mechanism mediating the
clinical effects of antipsychotic treatments.

Antipsychotic drugs selectively suppress conditioned
avoidance response. Using a two-way active avoidance response paradigm, we examined the role of druginduced interoceptive state in the mediation of avoidance-suppressive effect. In Experiment 1, we found that
rats intermittently treated with olanzapine (OLZ) (1.0
mg/kg, s.c.) or haloperidol (0.03 mg/kg, s.c.) on the 1st
day of a 3-day cycle for seven cycles exhibited a progressive across-session decline in avoidance responding,
despite the fact that they exhibited a comparable high
level of avoidance responding on the 3rd day of each
cycle during the drug-free retraining session. In Experiments 2 and 3, rats that were previously treated with
OLZ (0.5-2.0 mg/kg, s.c.) or risperidone (0.2-1.0 mg/kg)

Key words: conditioned avoidance response; drug memory; haloperidol; interoceptive drug state; olanzapine;
rat; risperidone

olytics and antidepressants do not have this selectivity.
Thus, the antiavoidance effect is frequently used as a validated behavioral index of ‘antipsychotic’ property. Most
work in preclinical psychopharmacology has used the rat
CAR model as a simple screening tool to identify chemical compounds with potential antipsychotic activity, and
the majority of the work relies on the acute treatment
effect. Little attention, however, has been paid to understand the behavioral mechanisms underlying the antiavoidance effect of antipsychotics. We recently addressed
this issue (Li, 2007). We used a repeated drug treatment
regimen to better mimic clinical treatment conditions
and found that rats treated with haloperidol (HAL), risperidone (RIS), or olanzapine (OLZ) daily for 7 consecutive days showed a progressive across-session decline
in avoidance responding. We also found that rats previously treated with HAL and retested under the same
dose of HAL after their avoidances recovered to the pre-

Introduction
Rat conditioned avoidance response (CAR) model is an
instrumental conditioning paradigm, in which rats are
trained to make an active motor response to avoid footshock (Bolles, 1970). In a typical CAR experiment, a rat is
placed in a two-compartment shuttle box and presented
with a conditioned stimulus (CS, e.g., white noise), followed by an aversive unconditioned stimulus (US, e.g.,
footshock). After several CS-US pairings, the rat typically runs from one compartment to another during the
CS (before the onset of the US), hence, avoiding the US.
The CAR model is a well-established preclinical test
for antipsychotic activity with high predictive validity
(Arnt, 1982; Natesan, et al., 2006; Wadenberg, et al., 2001).
All currently used antipsychotic drugs at the clinical relevant doses, selectively suppress avoidance responding
while leaving escape response intact. In contrast, anxi1
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drug level, still showed fewer avoidances than when
they were first tested. This finding indicates that HAL
treatment may induce a ‘memory-like’ mechanism that
allows the animal to ‘remember’ how to perform under
the influence of drug in the avoidance responding situation. This ‘memory-like’ mechanism is likely driven
by the interoceptive state caused by the antipsychotics
(Overton, 1979; Schechter and Cook, 1975) and may play
an important role in the maintenance of decreased avoidance responding across sessions.
The notion that the drug-induced interoceptive state(s)
may be directly involved in the antipsychotic effects
is relatively new, although preclinical studies such as
those based on drug discrimination and state-dependent
learning have long recognized the distinct drug states
induced by typical and atypical antipsychotics (Goudie,
et al., 1998; Overton, 1979; Porter, et al., 2005; Porter, et
al., 2000). In this study, we report three experiments that
further examined the role of the antipsychotic-induced
interoceptive state in the antiavoidance (antipsychotic)
effects of antipsychotic drugs. In Experiment 1, using a
between-subjects design and an intermittent (on-off-on)
drug treatment regimen, we tested the effects of repeated
HAL (0.03 mg/kg, s.c.) and OLZ (1.0 mg/kg, s.c.) treatment (once every 72 h) on avoidance responding over
seven nonconsecutive test sessions. During the ‘off’ days,
rats were retrained drug-free to maintain a high level of
avoidance. We found the same progressively enhanced
disruption on avoidance responding, as we observed in
rats tested in the consecutive schedule, despite the fact
that they all exhibited a high level of avoidance immediately prior to each drug session (e.g. during the drug-free
retraining sessions). In the subsequent HAL tests, when
all the rats were tested under HAL (0.03 mg/kg, s.c.),
those that were previously treated with OLZ showed
significantly lower avoidance responding than did those
that had previously received the vehicle, even though
both groups were exposed to HAL for the first time, suggesting that the antipsychotic drug state induced by OLZ
may have some similarities to that induced by HAL. In
Experiments 2 and 3, we examined this mechanism by
giving naive rats various doses of OLZ (Experiment 2) or
RIS (Experiment 3) during the acquisition phase of avoidance conditioning, retrained them drug-free for a period
of 3 weeks, and then tested their avoidance responding
under OLZ (1.0 mg/kg, s.c.) or RIS (0.33 mg/kg, s.c.).
We reasoned that if the antipsychotic-induced interoceptive drug state is one of the mechanisms that maintain
the antiavoidance effect of antipsychotics over time, we
should still be able to observe that rats previously treated
with OLZ or RIS during the acquisition phase (before the
acquisition of avoidance behavior) would still show a
stronger response to OLZ or RIS respectively after they
had acquired high avoidance response. Results were
consistent with our prediction.

Mead & Li

in

Journal

of

P s y c h o p h a r m a c o l o g y 23 (2009)

Materials and methods
Animals
Male Sprague-Dawley rats (226-250 g upon arrival,
Charles River, Portage, MI) were housed two per cage,
in 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages
lined with aspen shavings. The colony temperature was
maintained at 21 ± 1º C with a relative humidity of 55%60%, with water and food available ad libitum. All behavioral tests were conducted during the light phase of a 12
h light-dark cycle (with light on between 6:00 a.m. and
6:00 p.m.). Rats were allowed at least 1 week of habituation to the animal facility before being used in experiments. All protocols were approved by the University of
Nebraska–Lincoln Animal Care and Use Committee.
Drugs
The injection solutions of HAL (5 mg/mL, Sabex Inc,
Quebec, Canada) and chlordiazepoxide (CDP, SigmaAldrich, St. Louis, MO) were obtained by mixing drugs
with sterile water. OLZ (Toronto Research Chemicals
Inc, Ontario, Canada) and RIS (a gift from the NIMH
drug supply program) were dissolved in 1%-1.5% glacial acetic acid in sterile water. Citalopram (CIT, Toronto
Research Chemicals Inc., Ontario, Canada) was dissolved in 0.9% physiological saline. HAL, OLZ, RIS, and
CIT were administered subcutaneously (s.c.) 1 h before
avoidance training or testing, whereas CDP was injected
0.5 h before avoidance training (Li, et al., 2007).
Apparatus
Six identical two-way shuttle boxes custom designed
and manufactured by Med Associates (St. Albans, VT)
were used. Each box was housed in a ventilated, soundinsulated isolation cubicle (96.52 cm W × 35.56 cm D ×
55.88–63.5 cm H). Each box was 64 cm long, 30 cm high
(from grid floor), and 24 cm wide and was divided into
two equal-sized compartments by a partition with an
arch style doorway (15 cm high × 9 cm wide at base).
A barrier (4 cm high) was placed between the two compartments, so the rats had to jump from one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a diameter of 0.48 cm, spaced 1.6 cm
apart center to center, through which a scrambled footshock (US, 0.8 mA, maximum duration: 5 s) was delivered by a constant current shock generator (Model ENV410B) and scrambler (Model ENV-412). Illumination was
provided by two houselights mounted at the top of each
compartment. The CS was a 76 dB white noise produced
by a speaker (ENV 224 AMX) mounted on the ceiling of
the cubicle, centered above the shuttle box. Background
noise (approximately 74 dB) was provided by a ventilation fan affixed at the top corner of each isolation cubicle.
All training and testing procedures were controlled by
Med Associates programs running on a computer.
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Avoidance conditioning and testing procedure
A regular training/testing session consisted of either 20
or 30 trials (see below for details). Each trial started with
the presentation of white noise (CS) for 10 s, followed by
a continuous scrambled footshock (maximum duration
= 5 s, 0.8 mA, US) on the grid floor. If a subject moved
from one compartment to the other within the 10 s of
CS presentation, it avoided the shock, and this shuttling
response was recorded as avoidance.If the rat remained
in the same compartment for more than 10 s and made a
crossing upon receiving the footshock, this response was
recorded as escape. If the rat did not respond during the
entire presentation of the shock, the trial was terminated
and escape failure was recorded.
Statistical analysis
The number of avoidance responses was used as the
main dependent variable. Avoidance data from the
repeated drug test sessions were expressed as mean
values ± SEM and were analyzed using a factorial
repeated measures analysis of variance (ANOVA) with
the between-subjects factor being treatment groups (e.g.
HAL, OLZ, RIS etc.), and the within-subjects factor being
the drug test sessions. To identify the group difference
on specific test sessions, one-way ANOVAs followed by
post-hoc Tukey (HSD) tests (for more than three groups)
or independent-samples T-tests (for two-group comparisons) were used. A conventional two-tailed level of significance at the 5% level was required.
Experiment 1: Effects of repeated intermittent HAL
(0.03 mg/kg) or OLZ (1.0 mg/kg) treatment on avoidance
responding This experiment was designed to examine
the role of antipsychotic-induced interoceptive state in
the potentiation of the antiavoidance effect of repeated
antipsychotic treatment, using an intermittent ‘on-offon’ 3-day treatment/test schedule. This schedule consisted of seven 3-day treatment/test cycles. The first day
was a drug treatment and CAR test session. Well-trained
rats (>70% avoidance in the last two training sessions)
were injected with HAL (0.03 mg/kg, s.c.), OLZ (1.0 mg/
kg, s.c.), or vehicle (sterile water) and tested in a 30-trial
CAR session. The second day was a drug-free resting
day, and the third day was a drug-free CAR retraining
day when all rats were retrained in the 30-trial CAR session. This cycle repeated for seven times. This schedule
ensured that immediately before each cycle of drug test,
the rats’ avoidance responding was recovered back to
the predrug level. If the drug-induced interoceptive state
is one of the important behavioral mechanisms underlying the potentiated antiavoidance effect associated with
repeated drug treatment, we would expect to see lower
avoidance only during the drug test sessions, and a progressive decline in avoidance responding across the drug
sessions. Another advantage of this schedule was that it
minimizes the possibility of drug accumulation, so the
observed potentiated effect could only be attributed to

the drug cue. At the end of this intermittent schedule, all
rats were tested under HAL (0.03 mg/kg, s.c.) for three
consecutive sessions to examine whether previous OLZ
experience potentiated later response to HAL as a way of
assessing the similarity between the HAL-induced and
OLZ-induced interoceptive states.
Experimental procedure
A total of 30 rats were first habituated to the avoidance boxes for 2 days. On each day, rats were placed in
the box and allowed to explore the entire box for 20 min.
Rats were then trained for a total of eleven sessions (30
trials/session) over a 17-day period. At the end of the
training session, 23 rats had reached training criterion (at
or above 70% avoidance, or 21 trials, by the last 2 training
days), and they were randomly assigned to three groups
(n =7 vehicle, n =8 HAL, n = 8 OLZ) and started the intermittent ‘on-off-on’ 3-day treatment/test schedule. On
Day 1, rats were injected with HAL (0.03 mg/kg), OLZ
(1.0 mg/kg), or vehicle (sterile water) subcutaneously 1
h before being placed in the apparatus and tested. The
same procedure as used during the training was used for
the drug testing. On Day 2, rats were left alone in their
home cages. On Day 3, rats were retrained. This cycle
repeated for seven times over a period of 21 days. One
day after the end of the seventh cycle, all three groups
were injected with HAL (0.03 mg/kg, s.c.) and tested for
three additional sessions.
Experiment 2: Effects of OLZ treatment (0.5, 1.0 and 2.0
mg/kg) during the avoidance training on later avoidance responding to OLZ (1.0 mg/kg) This experiment
examined whether previous drug experience during
the acquisition phase of CAR might persist and cause
a potentiated OLZ response later. Forty-five rats were
randomly assigned to five groups (n =9/ group): vehicle (sterile water), OLZ 0.5, 1.0, 2.0 mg/kg, and CDP 10.0
mg/kg. After 2 days of habituation to the CAR boxes, all
rats were trained in a 20-trial CAR session for 7 consecutive days. Each daily training session started 1 h after
the OLZ or vehicle injection, or 30 min after CDP injections. One day later, the learning effect was assessed in
three drug-free avoidance testing sessions in which only
the CS was presented for 20 trials (no shock US). During these 10 days of the training/testing period, the rat’s
body temperature was also measured, using a probe
(lubricated with mineral oil) inserted in the rectum (Thermalert TH-5, Physitemp, Clifton, NJ, USA) before and
after each session. Because these data were not relevant to
the question addressed here, they were not reported here
but were reported in a separate paper (Mead, et al., 2008).
After 3 days of resting, all rats were retrained (drugfree)
to reacquire avoidance responding in 10 sessions (30 trials/ session) over 15 days. At the end of the training session, 35 rats had reached the training criteria (at or above
70% avoidance on the last 2 training days). These rats
were classified into two groups: one group consisting of
rats that were previously treated with OLZ (n = 11 of
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27 rats, OLZ 0.5, 1.0, 2.0 mg/kg, s.c., collectively termed
the ‘Olanzapine Experience’ group), and one group consisting of rats that were previously treated with either
vehicle orCDP (n = 13 of 18, termed the ‘No Olanzapine
Experience’ group). They were then treated with 1.0 mg/
kg of OLZ and tested for 3 consecutive days.
Experiment 3: Effects of RIS treatment (0.2, 0.33, and 1.0
mg/kg) during the avoidance training on later avoidance responding to RIS (0.33 mg/kg) This experiment
was identical to Experiment 2 with the following exceptions. First, 48 rats were used and randomly assigned to
six groups (n = 8/group): vehicle (sterile water), RIS 0.2,
0.33, 1.0 mg/kg, CDP 10.0 mg/kg and CIT 10.0 mg/kg.
Second, during the seven daily CAR test sessions under
drug and three daily CAR drug-free test sessions, all rats
were also tested for the startle reflex immediately after
being removed from the CAR boxes (these data were not
relevant to this study and are not reported here). All rats
were then retrained (drug-free) to reacquire avoidance
responding in ten sessions (30 trials/session) over 18 days.
After retraining, 45 rats had reached training criteria (at
or above 70% avoidance on the last two training days).
These rats were classified into two groups: one group
consisting of rats that were previously treated with RIS
(n = 22, termed the ‘Risperidone Experience’ group), and
one group consisting of rats that were previously treated
with either vehicle, CDP or CIT (n = 23, termed the ‘No
Risperidone Experience’ group). They were then treated
with 0.33 mg/kg of RIS and tested for 3 consecutive days.
Results
Experiment 1: Effects of intermittent HAL (0.03 mg/kg) or
OLZ (1.0 mg/kg) treatment on avoidance responding
Figure 1A shows the effects of intermittent HAL and
OLZ treatment on avoidance responding across the
seven test cycles. Both HAL and OLZ suppressed avoidance responding on the first drug day, and this effect
was potentiated with each subsequent drug test (a progressive across-session decline). Interestingly, on all
drug-free retraining days, avoidance responding in both
groups fully recovered back to the predrug levels. On
the contrary, rats treated with vehicle maintained a high
level of avoidance responding throughout the entire testing period. This observation was confirmed by statistical
analysis. A repeated measures ANOVA using ‘Drug Session’ as a within-subject factor and ‘Treatment Group’
as a between-subjects factor showed a significant main
effect of ‘Treatment Group’ (F(2,20) =20.724, P <0.001),
‘Drug Session’ (F(6,120) = 14.017, P < 0.001), and a ‘Treatment Group’ × ‘Drug Session’ interaction (F(2,20) =13.987,
P < 0.001). Individual one-way ANOVAs and post hoc
Tukey tests on each drug-testing day showed that the
OLZ group differed significantly from the vehicle group
on each day (Figure 1A, all Ps < 0.003), and HAL differed
significantly from the vehicle group on days 4 through 7
(all Ps < 0.05).

To examine the similarity between the HAL and OLZinduced drug state mediating avoidance, and whether
previous antipsychotic treatment potentiated later
response to HAL, all rats were treated with HAL (0.05
mg/kg, s.c.) for three consecutive days 3 days after the
last retraining test (see Figure 1B). An independent-samples T-test revealed the previously HAL-treated group
showed significantly lower avoidance responses than the
previously vehicle-treated group on days 1 and 2 (Day 1:
t(13) = 3.443, P = 0.004, Day 2: t(13) = 2.412, P = 0.031),
indicating a potentiated effect of previous HAL treatment. The previously OLZ-treated group also differed
significantly from the vehicle group on days 1 and 2 (Day
1: t(13) = 2.879, P =0.021, Day 2: t(13) = 2.218, P = 0.045),
suggesting that previous OLZ treatment also potentiated
the HAL effect, and there was a similarity between the
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HAL and OLZ-induced interoceptive states. The previously OLZ-and HAL-treated groups did not differ from
each other on any day (all Ps > 0.05).
Experiment 2: Effects of OLZ treatment (0.5, 1.0 and 2.0 mg/
kg) during the avoidance training on later avoidance responding to OLZ (1.0 mg/kg)
OLZ treatment severely impaired the acquisition of
avoidance responding. Rats repeatedly treated with
three different doses of OLZ (0.5, 1.0, 2.0 mg/kg) during
the acquisition phase of the CAR paradigm did not show
any improvement in avoidance responding (Figure 2A).
In contrast, rats treated with CDP, 10 mg/kg or vehicle

(distilled water) showed a steady improvement throughout the training phase (repeated measures ANOVAs: a
significant main effect of ‘Treatment’: F(4,40) = 15.489, P
< 0.001; ‘Sessions’: F(6,240) = 3.506, P = 0.002; and ‘Treatment’ × ‘Sessions’ interaction, F(24,240) = 5.745, P < 0.001).
In the three subsequent drug-free CS-only test days, as
shown in Figure 2B, the OLZ rats still showed significantly lower avoidance responses than the other groups
(all Ps < 0.05). Detailed analysis of avoidance response
data was reported in Mead, et al. (2008).
After the 10 sessions of drug-free retraining, only those
rats that exhibited more than 70% avoidances in the last
two retraining sessions were used in the OLZ retests. As
can be seen in Figure 3, before the OLZ treatment, both
the OLZ experienced group and the nonexperienced
group had almost identical mean avoidance responses.
However, upon retesting, the rats with previous OLZ
experience showed a much lower level of avoidance
responding than those with no previous OLZ experience
over the three test sessions. Independent-samples T-tests
showed that there were significant differences on Day 1
(t(33) = -5.536, P < 0.001), Day 2 (t(33) = -3.133, P = 0.006)
and Day 3 (t(33) = -3.344, P = 0.004).
Experiment 3: Effects of RIS treatment (0.2, 0.33, and 1.0 mg/
kg) during the avoidance training on later avoidance responding to RIS (0.33 mg/kg)
Rats treated with 10 mg/kg of CDP), 10 mg/kg of CIT,
or vehicle (distilled water) showed a steady improvement throughout the training phase. RIS treatment dose
dependently impaired the acquisition of avoidance
responding as the RIS 1.0 group–but not RIS 0.2 and RIS
0.33 groups–showed fewer avoidances than the vehicle
group (Tukey HSD test, P < 0.001). In the three subsequent drug-free CS-only test days, as shown in Figure 4B,
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difference on Day 2 (t(43) = -2.089, P < 0.043), but not on
Day 1 (t(43) = -1.528, P = 0.135) nor Day 3 (t(43) = -1.157,
P = 0.254).
Discussion

only the RIS 1.0 group showed significantly fewer avoidance responses than the other drug groups (P <0.001).
After the 10 sessions of drug-free retraining, only those
rats that exhibited more than 70% avoidances in the last
two retraining sessions were used in the RIS retests. As
can be seen in Figure 5, before the RIS treatment, both the
RIS experienced group and the nonexperienced group
had almost identical mean avoidance responses. However, upon retesting, the rats with previous RIS experience showed a much lower level of avoidance responding
than those with no previous RIS experience. Independent-samples T-tests showed that there was a significant

Results from the three experiments provide additional
support to the idea that antipsychotic-induced interoceptive state may be one of the important behavioral mechanisms underlying the potentiated antiavoidance effect
of repeated antipsychotic treatments. In Experiment 1,
we found that repeated intermittent antipsychotic treatment could reliably produce an across-session decline
in avoidance responding. Rats repeatedly treated with
HAL and OLZ every 3rd day, still exhibit an across-session decline despite the ability to return to high avoidance levels in between drug treatments. In addition, we
found that when rats were tested under HAL (0.03 mg/
kg), those previously treated with OLZ showed significantly lower levels of avoidance responding than vehicle rats, even though both groups were treated with
HAL for the first time. In Experiments 2 and 3, rats previously treated with OLZ or RIS during the acquisition
phase showed significantly fewer avoidance responses
than those without such a drug experience during the
retests 3 weeks later, suggesting that rats that have experienced an antipsychotic may ‘remember’ that drug state
and respond accordingly. This increase of anti-avoidance
effect across multiple drug test sessions does not seem to
reflect simple drug accumulation effect, as the half-lives
of antipsychotics in the rat brain is 1.5 h for HAL (Cheng
and Paalzow, 1992), 2.5 h for OLZ (Aravagiri, et al., 1999),
and less than 4 h for RIS (van Beijsterveldt, et al., 1994),
and we observed that the progressively potentiated anti-
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avoidance effect persisted for at least 3 days (Experiment
1) and over a 3-week period (Experiments 2 and 3).
In Experiment 1, we found that repeated intermittent
HAL and OLZ treatment can reliably produce an acrosssession decline in avoidance responding. This finding is
consistent with one of the experiments reported in Li, et
al. (2007). In that experiment, one group of well-trained
rats (a within-subject design) received three doses of
HAL from 0.03, 0.05, to 0.07 mg/kg (in this order) on
an intermittent schedule, with drug-free retraining sessions inserted between two drug sessions. The rats were
then tested a second time under the same drug schedule. The avoidance-disruptive effect of HAL at the same
doses was much stronger in the 2nd round than in the
1st round. However, several limitations from that experiment prevent us from drawing a firm conclusion regarding the role of the interoceptive drug state in the antiavoidance potentiation. First, the exact source of the
potentiated antiavoidance response seen in the 2nd
round is not clear. This is because a higher dose of HAL
(e.g. 0.07 mg/kg) in the 1st round was always tested
prior to a lower dose of HAL in the second round (e.g.
0.03 mg/kg); thus, it is possible that the potentiated antiavoidance effect could be due to the repeated drug experience or due to the influence from the higher doses.
Second, only HAL (a typical antipsychotic drug) was
examined for the behavioral mechanism of antipsychotic
action. Other anti-psychotics, such as atypicals like OLZ
and RIS, were not examined. This study addressed these
limitations, and the results suggest that even atypical
drugs, such as OLZ and RIS, may work through a similar behavioral mechanism, e.g. by producing an antipsychotic-like interoceptive drug state that allows the animals to respond according to the drug state. Our results
are also consistent with recent reports by Samaha, et al.
(2007, 2008) who found that repeated intermittent HAL
treatment (e.g. daily injection) gained efficacy in disrupting avoidance responding across multiple sessions. What
is even more remarkable with our findings is the fact that
this potentiated efficacy persists even after rats were off
drug for weeks and being retrained, so that their avoidances were back at the pre-drug levels (see Figures 1A, 3,
and 5). It appears that once a rat is exposed to an antipsychotic drug, this drug experience stays with it for a long
period of time, and this memory-like drug effect is possibly mediated by the drug-induced interoceptive state.
Behaviorally, an antipsychotic drug may act as an occasion setter (Maes and Vossen, 1997), which sets the condition in which rats behave on the basis of their previous drug experience in the avoidance testing context, or
it may directly imprint the brain to create a drug ‘memory trace’ about avoidance responding under drug. This
proposition may explain why continuous HAL treatment
through osmotic minipumps lost efficacy in disrupting
avoidance responding (Samaha, et al., 2008; Samaha, et
al., 2007), as continuous drug treatment could not create

a discrete drug state that is time-locked with the avoidance testing context. Thus, it may lose its occasion-setting
property and not be able to direct animals’ behavior in the
avoidance testing situation. Using dopamine D2 receptor occupancy as a guide, Kapur, et al. (2003) suggests
that antipsychotic administration through minipumps
provides a better model of antipsychotic treatment in
the clinic, as only this mode of drug administration produces clinical-relevant D2 occupancies (60-80%), a condition found in patients with schizophrenia maintained
on medications (Kapur, et al., 2003). On the basis of the
current findings and that of Samaha, et al. (2007, 2008),
it seems that although continuous drug administration
provides a better model of pharmacodynamic and pharmacokinetic actions (e.g. D2 occupancy) of antipsychotics
than intermittent treatment, it may not provide a better
model of behavioral effects of antipsychotics, which show
a progressive enhancement over time (Agid, et al., 2003;
Kapur, et al., 2005), and only intermittent drug treatment
in rats produces such a pattern of effects (Li, et al., 2007;
Sun, et al., 2009).
So what are the possible neural bases of the drug statebased potentiated antipsychotic effect? We speculate that
it may have something to do with the drug-induced brain
changes, (e.g. neuroplasticity) because of its memorylike characteristics (Konradi and Heckers, 2001). These
changes thus, might include elevations in the number and
sensitivity of neuroreceptors (e.g. D2, receptors) (Samaha,
et al., 2008; Samaha, et al., 2007), changes in the immediate early gene expressions (e.g. c-fos, zif268, (ΔFosB)
(Grande, et al., 2004; Nguyen, et al., 1992; Robertson
and Fibiger, 1992; Robertson, et al., 1994) and associated
intracellular signaling pathways (e.g. DARPP-32, cAMP
and PKA phosphorylation in the striatopallidal neurons)
(Bateup, et al., 2008), or even adult neurogenesis (Kippin, et al., 2005). This issue needs further investigation.
The idea that antipsychotic-induced interoceptive state
may be an important mechanism underlying the potentiated anti-avoidance effect with repeated treatment is
also supported by the finding that rats that were previously treated with OLZ showed significantly lower levels of avoidance responding when tested under HAL
than the rats previously treated with vehicle, although
both groups were exposed to HAL for the first time. This
finding suggests that the antipsychotic-induced interoceptive state is transferable between drugs that create
a similar state (i.e. other antipsychotics with a different structure and receptor profile). This finding is complimentary to one of the findings from Li, et al. (2007).
In that report, they found that rats previously treated
with HAL continued to show the suppressed avoidance
responding when switched to OLZ. Collectively, both
findings suggest that there is a similarity between HAL
and OLZ-induced antipsychotic-specific interoceptive
state, as they can substitute for each other.
One prediction based on this drug (interoceptive state)
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dependent memory mechanism is that even if the drug
has been stopped and the avoidance responding has fully
recovered back to the predrug level, during the next exposure to antipsychotic treatment, the animals with a previous drug experience should show a greater response – a
prediction that was confirmed for both OLZ (Experiment
2) and RIS (Experiment 3). There is an interesting differential effect between the two widely prescribed drugs.
During the avoidance training phase, OLZ impaired
the acquisition of avoidance response at all three dosage
levels, whereas RIS suppressed the avoidance acquisition
only at the highest dosage level. During the drug retests,
OLZ showed a stronger reexposure effect, as it caused
a significant group difference on each of the three test
sessions, whereas RIS showed a weaker effect as it only
caused a significant group difference on the second session. One possible explanation lies in the differences in the
receptor binding profiles. OLZ has high affinity to dopamine D1, D2, D3, D4, serotonin 5-HT2, histaminic H1, α-1
adrenergic and muscarinic M1-M5 receptors. RIS shows
high affinity for D2 and 5-HT2A, as well as affinity for
D1, D4, α-1 adrenergic, and α-2 adrenergic and histamine
H1 receptors (Miyamoto, et al., 2005). The exact binding
differences accounting for their differential potentiated
effect in avoidance model are not clear and need future
investigation. Another more likely explanation is the difference in the efficacy of OLZ and RIS doses used in the
retests. OLZ at 1.0 mg/kg may be more efficacious than
RIS at 0.33 mg/kg, thus, producing a stronger potentiated
effect. This point is also supported by the finding that
OLZ 1.0 mg/kg impaired the acquisition of avoidance
response, whereas RIS 0.33 mg/kg did not. It is thus possible that, had we used a higher dose of RIS (e.g. 1.0 mg/
kg), we could have seen the same level of potentiation.
Clinical observations indicate that antipsychotic action
starts early and increases in magnitude with repeated
treatment (Agid, et al., 2003; Agid, et al., 2006; Emsley,
et al., 2006; Glick, et al., 2006; Kapur, et al., 2005; Leucht,
et al., 2005; Raedler, et al., 2007). However, animal models that faithfully capture this time course of action are
few. This study represents an advance of our previous
work (Li, et al., 2007) and further supports the idea that
rat avoidance responding model based on the repeated
drug treatment regimen is capable of mimicking several important features of clinical effects of antipsychotic
treatment. It also provides a clue on the behavioral mechanism of antipsychotic action in the treatment of schizophrenia. Our previous work (Li, et al., 2007) and a recent
one (Li, et al., accepted) suggest that antipsychotic drugs
suppress avoidance responding by weakening the motivational salience of the CS. This observation, together
with the current findings, suggests that repeated antipsychotic treatment may disrupt avoidance responding
by two distinct mechanisms: (a) weakening the motivational salience of the CS and (b) providing an interoceptive drug state that maintains the weakening effect on
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motivational salience of the CS over time. To carefully
extrapolate to clinical treatment, we would propose a
hypothesis that antipsychotic drugs may achieve their
antipsychotic effect through a dual action: (a) selectively
weakening the aberrant motivational salience of stimuli
(e.g., psychotic thoughts or abnormal perceptions, internal and external cues) (Kapur, 2003); and (b) producing a
drug interoceptive state that allows the weakening effect
on the motivational salience of stimuli to be maintained
over time. Practically, this study may also provide support for the intermittent drug treatment regimen to be
tried in the clinic. Currently, the most common practice
in the clinic is to treat patients with antipsychotics on the
daily basis which produces approximately 60%-80% of
dopamine D2 receptor occupancy (Kapur, 1998). As it is
widely known that antipsychotic treatment carries many
side effects, including EPS and excess weight gain, an
intermittent schedule may be an efficient and safer alternative warranting further research. A recent study shows
that dosing every 2-3 days is sufficient to maintain antipsychotic efficacy in schizophrenic patients (Remington,
et al., 2005). These findings may suggest that upon initial exposure, physiological events may be initiated that
enhance the antipsychotic’s effects beyond its presence
at the receptor, thereby not requiring constant binding at
the receptor every day to be efficacious.
In summary, this study confirms that repeated antipsychotic treatment induces an interoceptive drug state that
mediates the potentiated antiavoidance effect of antipsychotics (HAL, OLZ and RIS) over multiple drug test
sessions. This drugstate-dependent ‘memory-like’ mechanism allows animals to make avoidance responses
according to the drug state that they experience and can
last for weeks. This mechanism may also be responsible for the clinical effects of repeated antipsychotic treatments in schizophrenia.
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